Loading...
Trastuzumab combined with first-line chemotherapy is standard treatment for patients with HER2+ esophagogastric adenocarcinoma. However, subsequent trials of other HER2-targeted agents, including lapatinib, pertuzumab, and trastuzumab emtansine, have failed to show effectiveness in this disease.
Trastuzumab deruxtecan is an antibody drug conjugate with a humanized, monoclonal anti-HER2 antibody bound to a cytotoxic topoisomerase I inhibitor via a cleavable tetrapeptide linker. To evaluate trastuzumab deruxtecan in this setting, investigators in Japan and South Korea conducted an industry-sponsored, multicenter, open-label, randomized, phase II trial (DESTINY-Gastric01) involving 187 patients with HER2+ gastric cancer (immunohistochemical ana…